Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 20 de 78
Filtrar
Más filtros











Base de datos
Intervalo de año de publicación
1.
Eur J Pharm Biopharm ; 103: 179-191, 2016 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-27063592

RESUMEN

Lercanidipine is a vasoselective dihydropyridine calcium antagonist, mainly used for the treatment of hypertension and angina pectoris. However, it suffers from food dependent absorption, poor solubility, low permeability and considerable first pass metabolism, resulting in highly variable and low bioavailability of 10%. Nanoparticles of lercanidipine were incorporated in fast dissolving oral films (FDO) via preparation of nanosuspension by evaporative antisolvent precipitation method. Prepared nanosuspensions were incorporated in FDO without lyophilizing or spray drying. Two nanosuspensions containing PEG 400 and TPGS 1000 as stabilizers, were selected further for incorporation in FDO. Physicochemical and mechanical properties of the optimized films were observed to be within acceptance criteria. SEM images as well as FTIR chemical images of oral films show uniform distribution of nanoparticles in polymeric matrix. The DSC and XRD results proved the poorly crystalline nature of lercanidipine. However thermal processing of film induces crystallinity in hypromellose which results in embedding of amorphous drug nanoparticles in semicrystalline polymeric matrix. Superior dissolution and permeability properties of nanoparticles were confirmed by in vitro dissolution studies and about 4.5-folds higher ex vivo drug permeation was observed from formulation through porcine buccal mucosa. This may give the clue for enhancement of bioavailability in vivo via improving orotransmucosal absorption.


Asunto(s)
Bloqueadores de los Canales de Calcio/administración & dosificación , Dihidropiridinas/administración & dosificación , Nanopartículas , Administración Oral , Animales , Bloqueadores de los Canales de Calcio/química , Dihidropiridinas/química , Técnicas In Vitro , Mucosa Bucal/metabolismo , Permeabilidad , Solubilidad , Espectroscopía Infrarroja por Transformada de Fourier , Porcinos , Difracción de Rayos X
2.
J Pharm Bioallied Sci ; 8(4): 314-320, 2016.
Artículo en Inglés | MEDLINE | ID: mdl-28216956

RESUMEN

BACKGROUND: The impact of diabetes on health-care expenditures has been increasingly recognized. To formulate an effective health planning and resource allocation, it is important to determine economic burden. OBJECTIVE: The objective of this study is to assess the cost of illness (COI) for diabetic inpatients with or without complications. METHODOLOGY: The study was conducted in the medicine wards of tertiary care hospital after ethical approval by the Institutional Ethical Committee. A total of 116 each diabetic with or without complications were selected and relevant data were collected using COI questionnaire and data were analyzed using SPSS version 20. Mann-Whitney U test is used to assess the statistical significant difference in the cost of treatment of diabetes alone and with complications'. P ≤ 0.05 was considered statistically significant. RESULTS: Total COI includes the cost of treatment, investigation, consultation fee, intervention cost, transportation, days lost due to work, and hospitalization. The median of total COI for diabetic care without any complication was Rs. 22,456.97/- per patient per annum and with complication was Rs. 30,634.45/-. Patients on dialysis had to spend 7.3 times higher, and patients with cardiac intervention had to spend 7.4 times higher than diabetic patients without any complication. CONCLUSION: Treatment costs were many times higher in patients with complications and with cardiac and renal interventions. Complications in diabetic patients will increase the economic burden to family and also to the society.

3.
Indian J Pharm Sci ; 77(4): 367-75, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26664051

RESUMEN

Nasal drug delivery has now been recognized as a promising route for drug delivery due to its capability of transporting a drug to systemic circulation and central nervous system. Though nasal mucosa offers improved bioavailability and quick onset of action of the drug, main disadvantage associated with nasal drug delivery is mucocilliary clearance due to which drug particles get cleared from the nose before complete absorption through nasal mucosa. Therefore, mucoadhesive polymeric approach can be successfully used to enhance the retention of the drug on nasal mucosal surface. Here, some of the aspects of the stimuli responsive polymers have been discussed which possess liquid state at the room temperature and in response to nasal temperature, pH and ions present in mucous, can undergo in situ gelation in nasal cavity. In this review, several temperature responsive, pH responsive and ion responsive polymers used in nasal delivery, their gelling mechanisms have been discussed. Smart polymers not only able to enhance the retention of the drug in nasal cavity but also provide controlled release, ease of administration, enhanced permeation of the drug and protection of the drug from mucosal enzymes. Thus smart polymeric approach can be effectively used for nasal delivery of peptide drugs, central nervous system dugs and hormones.

4.
Indian J Pharm Sci ; 77(3): 249-57, 2015.
Artículo en Inglés | MEDLINE | ID: mdl-26180269

RESUMEN

Pharmaceutical research is focused in designing novel drug delivery systems to improve the bioavailability of poorly water soluble drugs. Self-microemulsifying drug delivery systems, one among the lipid-based dosage forms were proven to be promising in improving the oral bioavailability of such drugs by enhancing solubility, permeability and avoiding first-pass metabolism via enhanced lymphatic transport. Further, they have been successful in avoiding both inter and intra individual variations as well as the dose disproportionality. Aqueous insoluble drugs, in general, show greater solubility in lipid based excipients, and hence they are formulated as lipid based drug delivery systems. The extent of solubility of a hydrophobic drug in lipid excipients i.e. oil, surfactant and co-surfactant (components of self-microemulsifying drug delivery systems) greatly affects the drug loading and in producing stable self-microemulsifying drug delivery systems. The present review highlighted the influence of physicochemical factors and structural features of the hydrophobic drug on its solubility in lipid excipients and an attempt was made to explore the role of each component of self-microemulsifying drug delivery systems in the formation of stable microemulsion upon dilution.

5.
J Pharm (Cairo) ; 2014: 864901, 2014.
Artículo en Inglés | MEDLINE | ID: mdl-26556205

RESUMEN

A simple, precise, accurate, rapid, and sensitive reverse phase high performance liquid chromatography (RP-HPLC) method with UV detection has been developed and validated for quantification of naringin (NAR) in novel pharmaceutical formulation. NAR is a polyphenolic flavonoid present in most of the citrus plants having variety of pharmacological activities. Method optimization was carried out by considering the various parameters such as effect of pH and column. The analyte was separated by employing a C18 (250.0 × 4.6 mm, 5 µm) column at ambient temperature in isocratic conditions using phosphate buffer pH 3.5: acetonitrile (75 : 25% v/v) as mobile phase pumped at a flow rate of 1.0 mL/min. UV detection was carried out at 282 nm. The developed method was validated according to ICH guidelines Q2(R1). The method was found to be precise and accurate on statistical evaluation with a linearity range of 0.1 to 20.0 µg/mL for NAR. The intra- and interday precision studies showed good reproducibility with coefficients of variation (CV) less than 1.0%. The mean recovery of NAR was found to be 99.33 ± 0.16%. The proposed method was found to be highly accurate, sensitive, and robust. The proposed liquid chromatographic method was successfully employed for the routine analysis of said compound in developed novel nanopharmaceuticals. The presence of excipients did not show any interference on the determination of NAR, indicating method specificity.

6.
Value Health ; 17(7): A601, 2014 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-27202077
10.
Value Health ; 17(7): A796, 2014 Nov.
Artículo en Inglés | MEDLINE | ID: mdl-27202983
12.
J Adv Pharm Technol Res ; 4(3): 134-40, 2013 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-24083200

RESUMEN

Informed consent is an ethical and legal requirement for research involving human participants. It is the process where a participant is informed about all aspects of the trial, which are important for the participant to make a decision and after studying all aspects of the trial the participant voluntarily confirms his or her willingness to participate in a particular clinical trial and significance of the research for advancement of medical knowledge and social welfare. The concept of informed consent is embedded in the principles of Nuremberg Code, The Declaration of Helsinki and The Belmont Report. Informed consent is an inevitable requirement prior to every research involving human being as subjects for study. Obtaining consent involves informing the subject about his or her rights, the purpose of the study, procedures to be undertaken, potential risks and benefits of participation, expected duration of study, extent of confidentiality of personal identification and demographic data, so that the participation of subjects in the study is entirely voluntary. This article provides an overview of issues in informed consent: The obligations of investigator, sponsor and Institutional Review Board to protect rights and welfare of human research subjects. It discusses about the basic elements of informed consent and the process to be followed while obtaining informed consent. Some of the circumstances under which informed consent can be waived and ethical challenges faced by physicians in obtaining informed consent from subjects are also highlighted in this article.

13.
Eur J Pharm Sci ; 50(3-4): 353-65, 2013 Nov 20.
Artículo en Inglés | MEDLINE | ID: mdl-23954456

RESUMEN

Catechin is a known hepatoprotective and anticancer agent but has limited bioavailability. Its apoptotic signaling pathway in human hepatocellular carcinoma is vaguely explored. Thus, this study was designed to explore cytotoxicity by MTT assay, induction of apoptosis via DNA fragmentation, nuclear staining, bivariate flow cytometric analysis using annexin V- FITC and propidium iodide, cell cycle analysis and apoptotic markers by RT-PCR and western blotting in HepG2 cells. To increase the bioavailability and selectivity to cancer cells, various liposomes of catechin viz., conventional, charged and PEGylated forms were prepared by film hydration method and evaluated for cytotoxicity in vitro in HepG2 cells and in in vivo in EAC-induced liquid tumor model. Catechin and catechin liposomes inhibited the growth of HepG2 cell lines at concentrations 100-200 µg mL(-1) depending on the length of exposure. It induced apoptosis and inhibited G2/M phase in cell cycle analysis. Catechin downregulated Bcl-2, initiated the release of cytochrome c into the cytosol and upregulated Bax, caspase-3,-9 and p53 in the HepG2 cells. Catechin and its liposomal formulation, at a dose of 200mg/kg body weight was found to be significantly (p<0.05) effective in inhibiting percentage increase in body weight and enhancing the mean survival time. Deviated hematological parameters, antioxidant parameters (superoxide dismutase, catalase and lipid peroxidation) and LFT in tumor bearing mice were found to be significantly (p<0.05) restored towards normal after treatment with catechin and its liposomes.


Asunto(s)
Antineoplásicos/administración & dosificación , Catequina/administración & dosificación , Animales , Carcinoma de Ehrlich/tratamiento farmacológico , Caspasa 3/genética , Caspasa 3/metabolismo , Caspasa 9/genética , Caspasa 9/metabolismo , Proliferación Celular/efectos de los fármacos , Supervivencia Celular/efectos de los fármacos , Química Farmacéutica , Citocromos c/genética , Citocromos c/metabolismo , Células Hep G2 , Humanos , Liposomas , Ratones , Proteínas Proto-Oncogénicas c-bcl-2/genética , Proteínas Proto-Oncogénicas c-bcl-2/metabolismo , Proteína p53 Supresora de Tumor/genética , Proteína p53 Supresora de Tumor/metabolismo , Proteína X Asociada a bcl-2/genética , Proteína X Asociada a bcl-2/metabolismo
14.
Curr Drug Deliv ; 10(3): 336-42, 2013 Jun.
Artículo en Inglés | MEDLINE | ID: mdl-23410070

RESUMEN

psyllium, a medicinally active gel forming natural polysaccharide and a dietary fiber has been used as a medicine in myriad of conditions such as constipation and inflammatory bowel syndrome. One of its more recent uses that have received attention has been its ability to reduce blood sugar levels in diabetics. Therefore present work is an attempt to formulate anti diabetic drug Metformin as a controlled release floating delivery making use of pysllium as release retardant and to assist the drug in stabilizing blood sugar level in type II diabetics. Drug and excipients compatibility studies were monitored by thermal analysis using differential scanning calorimeter (DSC) and Fourier transform infra red (FTIR). The DSC thermogram and FTIR of drug and drug-polymer mixture did not reveal any incompatibility. psyllium was tried in different concentrations along with other polymers like HPMC K15M and carbopol 940 to achieve the desired release profile. The total drug: polymer ratio was kept between 1:0.4 to 1:0.5, and different polymer combinations were tried to achieve desired drug release for 12 hours. The prepared tablets were evaluated for in vitro release studies and floating behavior. Our conclusion from the present study indicated that pysllium could potentially be used in conjunction with other polymers to formulate controlled release formulations of anti-diabetic drugs to provide better control over blood glucose levels.


Asunto(s)
Sistemas de Liberación de Medicamentos , Hipoglucemiantes/química , Preparaciones de Plantas/química , Plantago , Preparaciones de Acción Retardada/química , Metformina/química
15.
Nanotechnology ; 23(1): 015602, 2012 Jan 13.
Artículo en Inglés | MEDLINE | ID: mdl-22156111

RESUMEN

Size and shape controlled synthesis remains a major bottleneck in the research on nanoparticles even after the development of different methods for their preparation. By tuning the size and shape of a nanoparticle, the intrinsic properties of the nanoparticle can be controlled leading tremendous potential applications in different fields of science and technology. We describe a facile route for the one pot synthesis of gold nanoparticles in water using monosodium glutamate as the reducing and stabilizing agent in the absence of seed particles. The particle diameter can be easily controlled by varying the pH of the reaction medium. Nanoparticles were characterized using scanning electron microscopy, UV-vis absorption spectroscopy, cyclic voltammetry, and dynamic light scattering. Zeta potential measurements were made to compare the stability of the different nanoparticles. The results suggest that lower pH favours a nucleation rate giving rise to smaller particles and higher pH favours a growth rate leading to the formation of larger particles. The synthesized nanoparticles are found to be stable and biocompatible. The nanoparticles synthesized at high pH exhibited a good electrocatalytic activity towards oxidation of nicotinamide adenine dinucleotide (NADH).


Asunto(s)
Materiales Biocompatibles/metabolismo , Oro/metabolismo , NAD/metabolismo , Nanopartículas/química , Nanotecnología/métodos , Animales , Materiales Biocompatibles/química , Línea Celular , Supervivencia Celular , Oro/química , Ratones , Nanopartículas/ultraestructura , Oxidación-Reducción , Tamaño de la Partícula , Glutamato de Sodio/química
16.
J Adv Pharm Technol Res ; 2(1): 2, 2011 Jan.
Artículo en Inglés | MEDLINE | ID: mdl-22171284
17.
J Young Pharm ; 3(2): 155-62, 2011 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-21731362

RESUMEN

The Gulf cooperation council (GCC) region is considered as "Emerging market" for pharmaceutical export and bilateral trade. The understanding of the regulatory requirements of this region can be beneficial for pharmaceutical export. Some incidents of the year 2008-09, like recession or economic slowdown in highly well-off and regulated market of the EU and US, raised the demand for alternate destinations for business. The regulations of Gulf countries are encouraging the import of quality generic products, which can be good news to the Indian drug manufacturers.

18.
Drug Deliv ; 18(7): 511-22, 2011.
Artículo en Inglés | MEDLINE | ID: mdl-21793763

RESUMEN

CONTEXT AND OBJECTIVE: Plumbagin (2-methyl, 5-hydroxy, 1, 4-naphthoquinone), an anticancer agent is encapsulated either as conventional or long circulating liposomal formulations to enhance its biological half-life and antitumor efficacy. METHODS: The liposomes were prepared by thin film hydration method and in vitro characterization was carried out to examine the particle size, zeta potential, drug encapsulation efficiency and in vitro release. The optimized formulations were tested for pharmacokinetic and pharmacodynamic efficacy against mice bearing B16F1 melanoma. Also in vivo toxicity studies were carried out. RESULTS AND DISCUSSION: The optimum particle size and entrapment efficiency was observed at drug to lipid molar ratio of 1:20. The in-vitro release of plumbagin from the liposomal formulations in phosphate-buffered saline (pH 7.4) showed biphasic release with an initial burst release followed by sustained release phase. Elimination half life (T(½)) of pegylated, conventional and free plumbagin was 1305.76 ± 278.16, 346.87 ± 33.82 and 35.89 ± 7.95 min respectively. Further, plumbagin exhibited better antitumor efficacy in vivo when administered as long circulating liposomes with no signs of normal tissue toxicity. CONCLUSION: It can be concluded that the pegylated liposomes could provide a promising parenteral platform for plumbagin with enhanced plasma half-life and therapeutic efficacy.


Asunto(s)
Antineoplásicos Fitogénicos/administración & dosificación , Melanoma Experimental/tratamiento farmacológico , Naftoquinonas/administración & dosificación , Polietilenglicoles/química , Animales , Antineoplásicos Fitogénicos/farmacocinética , Antineoplásicos Fitogénicos/farmacología , Preparaciones de Acción Retardada , Femenino , Semivida , Liposomas , Masculino , Melanoma Experimental/patología , Ratones , Ratones Endogámicos C57BL , Naftoquinonas/farmacocinética , Naftoquinonas/farmacología , Tamaño de la Partícula , Pruebas de Toxicidad
19.
J Pharm Sci ; 100(8): 3517-3528, 2011 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-21523783

RESUMEN

The present study was aimed to formulate and compare the pharmacokinetic, biodistribution, pharmacodynamic, and toxicity profiles of free 5-hydroxy-1,4-naphthoquinone (juglone) with sterically stabilized liposomal form. The liposomes were optimized for size, zeta potential, entrapment efficiency (EE), and in vitro release properties. The optimized formulation had a mean size, zeta potential, and EE value of 137.1 nm, -43.1 mV, and 67.2%, respectively. In vitro release studies showed biphasic pattern with initial burst followed by sustained release over the study period, releasing about 61% after 24 h. In vitro cytotoxicity studies against melanoma cells indicated that liposomal juglone was more toxic than free juglone. Free juglone had short plasma half-life of about 2 h, whereas liposomal juglone exhibited significantly improved pharmacokinetics with a 12-fold increase in plasma half-life. Further, biodistribution studies indicated rapid renal elimination of free juglone, evidenced by its significant localization in kidneys. Conversely, the accumulation of liposomal juglone in kidneys reduced significantly with enhanced tumor localization, thereby resulting in enhanced antitumor activity. The histological studies revealed lower levels of nephrotoxicity for liposomal juglone compared with that of free juglone. To conclude, sterically stabilized liposomes could be a promising approach for the intravenous delivery of hydrophobic compounds such as juglone.


Asunto(s)
Antineoplásicos , Naftoquinonas , Animales , Antineoplásicos/farmacocinética , Antineoplásicos/uso terapéutico , Antineoplásicos/toxicidad , Línea Celular Tumoral , Supervivencia Celular/efectos de los fármacos , Química Farmacéutica , Femenino , Estimación de Kaplan-Meier , Liposomas , Masculino , Melanoma Experimental/tratamiento farmacológico , Ratones , Ratones Endogámicos C57BL , Microscopía Electrónica de Transmisión , Naftoquinonas/farmacocinética , Naftoquinonas/uso terapéutico , Naftoquinonas/toxicidad , Tamaño de la Partícula , Solubilidad , Propiedades de Superficie , Distribución Tisular , Ensayos Antitumor por Modelo de Xenoinjerto
20.
J Mater Sci Mater Med ; 22(4): 865-78, 2011 Apr.
Artículo en Inglés | MEDLINE | ID: mdl-21431353

RESUMEN

The purpose of this study was to develop sustained release formulation of anastrozole-loaded chitosan microspheres for treatment of breast cancer. Chitosan microspheres cross-linked with two different cross-linking agents viz, tripolyphosphate (TPP) and glutaraldehyde (GA) were prepared using single emulsion (w/o) method. A reverse phase HPLC method was developed and used for quantification of drug in microspheres and rat plasma. Influence of cross-linking agents on the properties of chitosan microspheres was extensively investigated. Formulations were characterized for encapsulation efficiency (EE), compatibility of drug with excipients, particle size, surface morphology, swelling capacity, erosion and drug release profile in phosphate buffer pH 7.4. EE varied from 30.4 ± 1.2 to 69.2 ± 3.2% and mean particle size distribution ranged from 72.5 ± 0.5 to 157.9 ± 1.5 µm. SEM analysis revealed smooth and spherical nature of microspheres. TPP microspheres exhibited higher swelling capacity, percentage erosion and drug release compared to GA microspheres. Release of anastrozole (ANS) was rapid up to 4 h followed by slow release status. FTIR analysis revealed no chemical interaction between drug and polymer. DSC analysis indicated ANS trapped in the microspheres existed in amorphous form in polymer matrix. The highest correlation coefficients (R (2)) were obtained for Higuchi model, suggesting a diffusion controlled mechanism. There was significant difference in the pharmacokinetic parameters (AUC(0-∞), Kel and t(1/2)) when ANS was formulated in the form of microspheres compared to pure drug. This may be attributed to slow release rate of ANS from chitosan microspheres and was detectable in rat plasma up to 48 h which correlates well with the in vitro release data.


Asunto(s)
Antineoplásicos Hormonales/administración & dosificación , Quitosano/química , Preparaciones de Acción Retardada/química , Microesferas , Nitrilos/administración & dosificación , Triazoles/administración & dosificación , Anastrozol , Área Bajo la Curva , Neoplasias de la Mama/tratamiento farmacológico , Cromatografía Líquida de Alta Presión/métodos , Difusión , Glutaral/química , Humanos , Concentración de Iones de Hidrógeno , Microscopía Electrónica de Rastreo/métodos , Tamaño de la Partícula , Polímeros/química , Espectroscopía Infrarroja por Transformada de Fourier/métodos
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA